Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX)‘s stock had its “neutral” rating reissued by BTIG Research in a research report issued to clients and investors on Wednesday.

A number of other analysts have also recently weighed in on VRX. Wells Fargo & Company restated a “sell” rating and issued a $19.50 price objective on shares of Valeant Pharmaceuticals International in a research note on Sunday, September 18th. Deutsche Bank AG started coverage on shares of Valeant Pharmaceuticals International in a research note on Tuesday, September 20th. They issued a “hold” rating and a $30.00 price objective for the company. RBC Capital Markets restated a “sector perform” rating on shares of Valeant Pharmaceuticals International in a research note on Tuesday, September 20th. Royal Bank Of Canada reduced their price objective on shares of Valeant Pharmaceuticals International from $36.00 to $35.00 and set a “sector perform” rating for the company in a research note on Wednesday, October 12th. Finally, J P Morgan Chase & Co restated a “neutral” rating on shares of Valeant Pharmaceuticals International in a research note on Tuesday, October 25th. Five equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and six have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $34.80.

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Valeant Pharmaceuticals International (NYSE:VRX) traded down 5.701% on Wednesday, hitting $15.465. 25,433,383 shares of the stock were exchanged. The stock’s market cap is $5.38 billion. The company’s 50 day moving average is $15.26 and its 200 day moving average is $21.79. Valeant Pharmaceuticals International has a 1-year low of $13.00 and a 1-year high of $101.40.

This article was originally published by and is the sole property of American Banking News. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/01/11/valeant-pharmaceuticals-international-inc-vrx-earns-neutral-rating-from-btig-research.html

Valeant Pharmaceuticals International (NYSE:VRX) last issued its quarterly earnings data on Tuesday, November 8th. The specialty pharmaceutical company reported $1.55 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.78 by $0.23. Valeant Pharmaceuticals International had a positive return on equity of 43.81% and a negative net margin of 22.17%. The firm earned $2.48 billion during the quarter, compared to analyst estimates of $2.49 billion. During the same quarter in the previous year, the firm posted $2.74 earnings per share. Valeant Pharmaceuticals International’s quarterly revenue was down 11.0% compared to the same quarter last year. On average, equities research analysts expect that Valeant Pharmaceuticals International will post $5.44 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/01/11/valeant-pharmaceuticals-international-inc-vrx-earns-neutral-rating-from-btig-research.html.

In other Valeant Pharmaceuticals International news, Director Pershing Square Capital Manage sold 3,476,690 shares of the company’s stock in a transaction dated Monday, December 12th. The shares were sold at an average price of $14.85, for a total transaction of $51,628,846.50. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Thomas W. Sr. Ross bought 5,000 shares of the business’s stock in a transaction on Wednesday, December 14th. The shares were acquired at an average price of $14.73 per share, for a total transaction of $73,650.00. Following the completion of the transaction, the director now owns 26,822 shares in the company, valued at approximately $395,088.06. The disclosure for this purchase can be found here. Company insiders own 16.37% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC increased its position in Valeant Pharmaceuticals International by 6.7% in the second quarter. Tower Research Capital LLC TRC now owns 6,405 shares of the specialty pharmaceutical company’s stock worth $129,000 after buying an additional 402 shares during the last quarter. Kistler Tiffany Companies LLC increased its position in Valeant Pharmaceuticals International by 95.5% in the third quarter. Kistler Tiffany Companies LLC now owns 5,567 shares of the specialty pharmaceutical company’s stock worth $137,000 after buying an additional 2,719 shares during the last quarter. US Bancorp DE increased its position in Valeant Pharmaceuticals International by 141.0% in the third quarter. US Bancorp DE now owns 5,745 shares of the specialty pharmaceutical company’s stock worth $141,000 after buying an additional 3,361 shares during the last quarter. D.A. Davidson & CO. increased its position in Valeant Pharmaceuticals International by 22.6% in the third quarter. D.A. Davidson & CO. now owns 5,980 shares of the specialty pharmaceutical company’s stock worth $146,000 after buying an additional 1,103 shares during the last quarter. Finally, Alps Advisors Inc. acquired a new position in Valeant Pharmaceuticals International during the second quarter worth about $206,000. Institutional investors own 64.95% of the company’s stock.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

5 Day Chart for NYSE:VRX

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.